MA29492B1 - Formulations stables de nanoparticules - Google Patents

Formulations stables de nanoparticules

Info

Publication number
MA29492B1
MA29492B1 MA30430A MA30430A MA29492B1 MA 29492 B1 MA29492 B1 MA 29492B1 MA 30430 A MA30430 A MA 30430A MA 30430 A MA30430 A MA 30430A MA 29492 B1 MA29492 B1 MA 29492B1
Authority
MA
Morocco
Prior art keywords
nanoparticles
stable formulations
formulations
methods
making
Prior art date
Application number
MA30430A
Other languages
English (en)
Inventor
Khawla Abdullah Abu-Izza
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of MA29492B1 publication Critical patent/MA29492B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES FORMULATIONS NANOPARTICULAIRES PHARMACEUTIQUEMENT STABLES DE SUBSTANCES MÉDICAMENTEUSES PEU SOLUBLES, LES PROCÉDÉS D'ÉLABORATION DE TELLES FORMULATIONS, ET LES PROCÉDÉS D'UTILISATION CORRESPONDANTS.
MA30430A 2005-05-05 2007-11-29 Formulations stables de nanoparticules MA29492B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67808605P 2005-05-05 2005-05-05

Publications (1)

Publication Number Publication Date
MA29492B1 true MA29492B1 (fr) 2008-05-02

Family

ID=38309654

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30430A MA29492B1 (fr) 2005-05-05 2007-11-29 Formulations stables de nanoparticules

Country Status (15)

Country Link
US (1) US20080038359A1 (fr)
EP (1) EP1895982A2 (fr)
JP (1) JP5483874B2 (fr)
KR (2) KR20080015077A (fr)
CN (1) CN101252914B (fr)
AU (2) AU2006336414B2 (fr)
BR (1) BRPI0611433A2 (fr)
CA (1) CA2606861C (fr)
IL (1) IL187128A0 (fr)
MA (1) MA29492B1 (fr)
NO (1) NO20076120L (fr)
NZ (1) NZ562559A (fr)
RU (1) RU2409352C2 (fr)
WO (1) WO2007086911A2 (fr)
ZA (1) ZA200708633B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7923478B2 (en) * 2006-12-28 2011-04-12 Bridgestone Corporation Nanoporous polymeric material and preparation method
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2013041944A1 (fr) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Procédé pour la préparation de candésartan cilexétil micronisé
CN104174468B (zh) * 2014-08-27 2016-06-15 上海延安药业有限公司 粘稠性药物锆珠研磨方法
IL307931A (en) * 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263310A (en) * 1974-03-02 1981-04-21 Boehringer Ingelheim Gmbh 8-Bromo-6-(o-chloro-phenyl)-4H-S-triazolo-[3,4,-c]-thieno-[2,3-e]-1,4-diazepines and salts thereof
US4322440A (en) * 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
CA2019719A1 (fr) * 1990-06-25 1991-12-25 William J. Thompson Bain de bouche
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
JPH05305226A (ja) * 1992-04-28 1993-11-19 Takeda Chem Ind Ltd 粒子及びその製造法
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
IL140276A0 (en) * 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
US6200590B1 (en) * 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP2003518038A (ja) * 1999-12-20 2003-06-03 ニコラス， ジェイ カークホフ， 流動床噴霧乾燥によるナノ粒子製造方法
FR2813306B1 (fr) * 2000-08-23 2005-10-21 Sanofi Synthelabo Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
US7105176B2 (en) * 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
AU2002234545A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
EP1365739A1 (fr) * 2001-02-05 2003-12-03 Pharmacia & Upjohn Company Composition pour administration par voie rectale d'un medicament antibacterien d'oxazolidinone
GB0127832D0 (en) * 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
WO2003047497A1 (fr) * 2001-12-06 2003-06-12 Ranbaxy Laboratories Limited Compositions d'isotretinoine nanoparticulaire
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
BR0215979A (pt) * 2002-12-13 2005-11-01 Jagotec Ag Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica
BR0318298A (pt) * 2003-05-07 2006-07-11 Ifac Gmbh & Co Kg composições para a liberação dirigida de fragráncias e aromas
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법

Also Published As

Publication number Publication date
CA2606861C (fr) 2012-08-07
NZ562559A (en) 2011-03-31
IL187128A0 (en) 2008-06-05
KR20080015077A (ko) 2008-02-18
KR20140002810A (ko) 2014-01-08
AU2006336414B2 (en) 2011-11-24
NO20076120L (no) 2007-11-27
AU2006336414A1 (en) 2007-08-02
US20080038359A1 (en) 2008-02-14
RU2007145055A (ru) 2009-06-10
HK1120417A1 (en) 2009-04-03
RU2409352C2 (ru) 2011-01-20
WO2007086911A2 (fr) 2007-08-02
WO2007086911A3 (fr) 2008-04-17
BRPI0611433A2 (pt) 2010-09-08
EP1895982A2 (fr) 2008-03-12
ZA200708633B (en) 2009-01-28
CA2606861A1 (fr) 2007-08-02
AU2010241245A1 (en) 2010-11-25
CN101252914B (zh) 2013-03-27
JP5483874B2 (ja) 2014-05-07
CN101252914A (zh) 2008-08-27
JP2008540439A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
MX2007002189A (es) Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
TW200501941A (en) Heterobifunctional polymeric bioconjugates
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
DK0938316T3 (da) Opioidantagonistholdig galenisk formulering
AU2003303458A1 (en) Ampholytic copolymer and use thereof
WO2006110776A3 (fr) Compositions a base de polymere et conjugues d'agents antimicrobiens
WO2004011611A3 (fr) Anticorps anti-taci et utilisations de ceux-ci
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
WO2006035417A3 (fr) Preparations de dihydropyrimidine
BR0014320A (pt) Composições de substâncias terapêuticas solúveis em tocol
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
WO2006138463A3 (fr) Compositions polymeres et conjugues de medicaments anti-inflammatoires non steroides
ECSP088203A (es) Dispersiones amorfas sólidas
WO2005065660A3 (fr) Formulations de ziprasidone
EP1483579A4 (fr) Conjugues de composes biologiquement actifs, methodes de preparation et d'utilisation des conjugues, formulation et applications pharmaceutiques obtenues a partir desdits conjugues
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
WO2006081363A3 (fr) Formulations orales pour l'administration de butanes catecholiques comprenant des composes ndga
WO2007021970A3 (fr) Formes pharmaceutiques stables et methodes d'utilisation de celles-ci
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
TW200738283A (en) Formulations of conjugated estrogens and bazedoxifene
DK1608344T3 (da) Orale cladribin-formuleringer